Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
144.85
+0.51 (0.35%)
Oct 30, 2026, 4:00 PM EST - Market closed
Protagonist Therapeutics Employees
Protagonist Therapeutics had 141 employees as of June 30, 2026. The number of employees increased by 11 or 8.46% compared to the same quarter last year. That makes Protagonist Therapeutics the 29,306th largest employer in the world and 3,724th in the United States.
Employees
141
Change (1Y)
11
Growth (1Y)
8.46%
Revenue / Employee
$1,999,943
Profits / Employee
$588,007
Market Cap
9.37B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 141 | 11 | 8.46% |
| Mar 31, 2026 | 131 | 7 | 5.65% |
| Dec 31, 2025 | 132 | 6 | 4.76% |
| Sep 30, 2025 | 128 | 2 | 1.59% |
| Jun 30, 2025 | 130 | 5 | 4.00% |
| Mar 31, 2025 | 124 | 0 | - |
| Dec 31, 2024 | 126 | 14 | 12.50% |
| Sep 30, 2024 | 126 | 15 | 13.51% |
| Jun 30, 2024 | 125 | 19 | 17.92% |
| Mar 31, 2024 | 124 | 21 | 20.39% |
| Dec 31, 2023 | 112 | 7 | 6.67% |
| Sep 30, 2023 | 111 | -11 | -9.02% |
| Jun 30, 2023 | 106 | -21 | -16.54% |
| Mar 31, 2023 | 103 | -19 | -15.57% |
| Dec 31, 2022 | 105 | -13 | -11.02% |
| Sep 30, 2022 | 122 | 6 | 5.17% |
| Jun 30, 2022 | 127 | 26 | 25.74% |
| Mar 31, 2022 | 122 | 39 | 46.99% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Twist Bioscience | 979 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
PTGX News
- 11 days ago - Protagonist Therapeutics price target raised to $160 from $155 at TD Cowen - TheFly
- 20 days ago - Protagonist Therapeutics assumed with an Outperform at Leerink - TheFly
- 21 days ago - Protagonist Therapeutics initiated with a Buy at UBS - TheFly
- 7 weeks ago - Protagonist Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 weeks ago - Protagonist Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 7 weeks ago - Protagonist Therapeutics announces $300M share repurchase program - TheFly
- 7 weeks ago - Protagonist Therapeutics Announces $300 Million Share Repurchase Program - Accesswire
- 7 weeks ago - Protagonist Therapeutics Slides: Corporate presentation - Filings